Follow-up study of the G7 hip implant with Vivacit-E or Longevity bearing
Follows adults with hip disease who receive the G7 dual mobility hip implant.
Plain-language title generated from the registry record
Registry title: G7 Dual Mobility With Vivacit-E or Longevity PMCF
Key facts
- Where
- Milan, ItalySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 80 who need a total hip replacement or a revision of an earlier hip replacement. It follows how safe the G7 Dual Mobility hip implant is over time.
- Age
- 18 to 80 years, and the skeleton must be fully grown.
- Sex
- All sexes can join.
- Disease stage
- Hip surgery is needed for at least one reason: osteoarthritis or avascular necrosis, rheumatoid arthritis, risk of dislocation, correction of a deformity, certain hip fractures or non-union, or a revision where other treatment or devices have failed.
- Earlier treatment
- A revision procedure is allowed when other treatment or devices have failed. The record sets no other prior treatment rule.
Main reasons for not taking part
- Active infection, sepsis or osteomyelitis at the affected joint
- Significant osteoporosis, osteomalacia or a metabolic disorder that may impair bone formation
- Hip replacement on the other side within 3 months before or planned within 3 months after this surgery
- Both hips operated at the same time
- Known pregnancy
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT05548972, who can take part
Where in Italy
- Istituto San SiroMilan, ItalyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Zimmer Biomet
- Trial code
- NCT05548972
- Record updated
- 15 June 2025
- Original description
This study is a global, multi-center, prospective, non-controlled, non-randomized, post-market clinical follow-up study. The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Dual Mobility Acetabular System when used with the Vivacit-E or Longevity polyethylene hip bearing and instrumentation in primary total and revision (total) hip arthroplastyRead full original descriptionShow less
Global, Multicenter and Prospective Post-Market Clinical Follow-Up Study of the G7® Dual Mobility Acetabular System With Vivacit-E® or Longevity® Poly Bearing & Instrumentation
This study is a global, multi-center, prospective, non-controlled, non-randomized, post-market clinical follow-up study. The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Dual Mobility Acetabular System when used with the Vivacit-E or Longevity polyethylene hip bearing and instrumentation in primary total and revision (total) hip arthroplasty
Inclusion: Patient is 18 to 80 years of age, inclusive; Patient is skeletally mature; Patient qualifies for (total) hip arthroplasty based on physical exam and medical history including at least one of the following:; Non-inflammatory degenerative joint disease, including osteoarthritis and avascular necrosis; Rheumatoid arthritis; Dislocation risks; Correction of functional deformity; Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques; Revision procedures where other treatment or devices have failed; Patient is willing and able to complete scheduled follow-up evaluations as described in the protocol and Informed Consent; Patient, or the patient's legally authorized representative (LAR), has participated in the Informed Consent process and is willing and able to sign an IRB/EC approved Informed Consent.
Exclusion: Patient has any concomitant disease which is likely to jeopardize the functioning or success of the implant; The patient is in a vulnerable population group such as:; a prisoner; a known alcohol or drug abuser; mentally incompetent or unable to understand what participation in this study entails; Patient is septic, has an active infection or has osteomyelitis at the affected joint; Patient has metabolic disorder(s) which may impair bone formation; Patient has distant foci of infections which may spread to the implant site; Patient has vascular insufficiency, muscular atrophy at the implant site or neuromuscular disease which are likely to jeopardize the outcome of the surgery; Patient has significant osteoporosis as defined by treating surgeon; Patient has osteomalacia; Patient has rapid joint destruction, marked bone loss or bone resorption apparent on pre-operative radiographs; Patient underwent contralateral THA within 3 months of planned index procedure or has a contralateral THA planned within 3 months of the index procedure; Patient is undergoing simultaneous bilateral THA; Patient is known to be pregnant.